New patent expiration for the drug Celgene REVLIMID – DrugPatentWatch
Annual Drug Patent Expiration for REVLIMID
Revlimid is a drug marketed by Celgene and included in one NDA. It is available from a single supplier. There are fifteen patents protecting this drug and three Paragraph IV challenges.
Drug patent litigation for REVLIMID.
This drug has three hundred and forty-seven patent family members in forty-one countries.
The generic ingredient in REVLIMID is lenalidomide. One registered supplier for this compound. Additional details are available on the lenalidomide profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
Make Better Decisions with DrugPatentWatch
» Start Your Free Trial Today «
Copyright © DrugPatentWatch. Originally published in Recently expired patent for the drug Celgene REVLIMID